Keith D. Eaton, MD, PhD

Keith D. Eaton, MD, PhD

Clinical Director – THN Oncology
Medical Director – Infusion and Pharmacy
Medical Director – Quality Safety and Value
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-940
Seattle, WA 98109-1023

Admin Contact

Melissa Roa

Specialty / Expertise

Head & Neck Cancer
Lung Cancer
Thyroid Cancer
Cancer of unknown primary

Research Interests

Targeted Therapies

Selected Active Clinical Trials

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. NCT01620190

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). NCT02088112

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. NCT01336634

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC). NCT02038647

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors. NCT02100007

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer. NCT01613768

Se xor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas (STARRS). NCT02213133

A Study Of PF-06664178 In Patients With Advanced Solid Tumors NCT02122146

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients. NCT01526928

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer. NCT02119650

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies. NCT00697632

Current Research Projects

A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene.
Role: Principal Investigator

Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus.
Role: Principal Investigator

Phase I/II, Open-Label, Randomized Study Of The Safety, Efficacy, and Pharmacokinetics of Erlotinib With or Without PF-02341066 in Patients With Advanced Non-Small Cell Adenocarcinoma of the Lung.
Role: Site Principal Investigator

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non‑Small Cell Lung Carcinoma Who Have EGFR-Positive Tumors.
Role: Site Principal Investigator

Registration Phase III Study of Lucanix (belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blind, Placebo-controlled Study of Lucanix Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy.
Role: Site Principal Investigator

Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: Co-Investigator

Phase 2, open-label single arm study of the efficacy and safety of PF‑02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus.
Role: Co-Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer.
Role: Co-Investigator

A Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN).
Role: Co-Investigator

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Role: Co-Investigator.

A Phase 2, Open-label Trial of PF-00299804 in Untreated Advanced Adenocarcinoma of the Lung in Never or Former Light Smokers.
Role: Co-Investigator

Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Role: Co-Investigator

Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation.
Role: Co-Investigator

A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Role: Co-Investigator


Dr. Eaton received his MD and PhD from the University of California, San Diego, CA. He completed his Internal Medicine Residency at the University of Washington, Seattle, WA. He was a Post-Doctoral Fellow in Oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA.

Selected Publications

Shiovitz S, Eaton KD. A 66-year-old woman with newly diagnosed oligometastatic non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Mar 1;10(3):297-301.

Chamberlain MC, Eaton KD, Fink J. Radiation-induced myelopathy: treatment with bevacizumab. Arch Neurol. 2011 Dec;68(12):1608-9.

Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK. Occult primary. J Natl Compr Canc Netw. 2011 Dec 1;9(12):1358-95.

Carr LL, Mankoff D, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman J, Martins RG. Phase II Study of Sunitinib in FDG-PET Positive, Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation. Clin Cancer Res. 2010 Sep 16. [Epub ahead of print] PubMed. PMID: 20847059.

Khanal Y, Eaton J, Pakish J, Yen P, Martins R, Carr L, Eaton K, Patel S. Survival disparities in non-small cell lung cancer patients receiving radiation treatment: An investigation of race and gender. JCREO. 2010. Vol. 2(3), pp. 29-34.

Eaton KD, Martins RG. Maintenance Chemotherapy in NSCLC. JNCCN. 2010 July. Vol.8(7).

Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2010 May 17.
[PubMed Abstract]

Chamberlain MC, Eaton KD, Fink JR, Tredway T. Intradural intramedullary spinal cord metastasis due to mesothelioma. J Neurooncol. 2009 Aug 20.

Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. Ann Thorac Surg. 2008; 86:1632-9.

Eaton KD , Frieze DF. Cancer Pain: Perspectives of a Medical Oncologist. Current Pain and Headache Reports 2008 August. 12(4):270-6 (2008).

Ettinger DS, Agulnik M, Cristea M, Eaton KD, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw. 2008 Nov;6(10):1026-60. Review.
[PubMed Abstract]

Bauman J, Eaton K, Martins RG. Treatment of Recurrent Squamous Cell Carcinoma of the Skin with Cetuximab. Arch Dermatol. 2007; 143(7):889-892.

Bauman JE, Eaton KD, Martins RG. Antagonism of Platelet-Derived Growth Factor Receptor in Non-Small Cell Lung Cancer: Rationale and Investigations. Clin Cancer Res. .

Laporta A, Eaton, KD, Surko, CM, Transition Between Curved and Angular Textures in Binary Fluid Convection. Phys. Rev. E 53: 570-6 (1996).

Baxter GW, Eaton KD, Surko, CM. Eckhaus Instability for Traveling Waves. Phys. Rev. A 46, 1735-8 (1992).

Eaton KD, Ohlsen DR, Yamamoto SY, Surko CM, Barten W, Lucke M, Kamps M, Kolodner P. Concentration Field in Traveling-Wave and Stationary Convection in Fluid Mixtures. Phys. Rev. A 43, 7105-8 (1991).

Last updated: April 2012